The Definitive Infrastructure for Modern Drug Development

Why It Matters

Accelerating enrollment and automating data flow cuts trial timelines and expenses, expanding patient access and improving the efficiency of drug development pipelines.

Key Takeaways

• 800+ research sites across US, Japan, Israel
• AI-driven eligibility modeling reduces protocol amendments
• Direct EHR-to-EDC capture cuts manual data entry time
• Real‑world patient identification boosts enrollment speed
• FHIR/HL7 integration ensures interoperable data flow

Pulse Analysis

Clinical trials have long struggled with slow patient recruitment, fragmented data capture and costly protocol amendments. Paradigm Health’s platform tackles these pain points by embedding AI‑driven eligibility modeling into the design phase, allowing sponsors to simulate real‑world patient pools and adjust criteria before a study launches. This proactive approach reduces the likelihood of mid‑trial amendments, which historically can add millions of dollars and months to development timelines. By leveraging a network that spans 800+ sites, the company can match trials with the most suitable locations based on actual patient availability and historical performance.

The platform’s integration layer uses FHIR and HL7 standards to pull structured and unstructured data directly from electronic health records, automatically populating electronic case report forms. This eliminates manual transcription, improves data fidelity, and speeds up source data verification. AI‑powered screening tools operate within provider workflows, flagging eligible patients in real time and guiding clinical research coordinators through enrollment steps. Continuous recruitment intelligence dashboards give sponsors visibility into screening volumes, eligibility rates, and enrollment progress, enabling rapid site‑level interventions to address bottlenecks.

From a market perspective, the solution positions Paradigm Health as a strategic partner for pharmaceutical companies seeking to de‑risk late‑phase and post‑approval studies. The ability to conduct trials within real‑world care settings reduces reliance on traditional research sites, potentially lowering per‑patient costs by up to 30% according to industry benchmarks. Moreover, the global footprint across the US, Japan and Israel opens pathways for multinational studies with harmonized data streams. As regulators increasingly endorse decentralized trial models, platforms that combine AI, interoperable data exchange and embedded site support are likely to become essential infrastructure for the next generation of drug development.